Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03404570 · ClinicalTrials.gov registry record · Phase 2
Exploratory Study to Assess the Efficacy and Safety of TC-5214 in the Treatment of Subjects With Palmar Hyperhidrosis
A Phase 2 study of Palmar Hyperhidrosis, sponsored by Atacama Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 3
- Study locations
NCT03404570: Completed Phase 2 study of Palmar Hyperhidrosis, sponsored by Atacama Therapeutics.
NCT03404570 is a Phase 2 study of Palmar Hyperhidrosis that has completed, run by Atacama Therapeutics. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03404570, a Phase 2 study of Palmar Hyperhidrosis, has completed, sponsored by Atacama Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a pilot exploratory study to evaluate the safety and efficacy of TC-5214 in subjects with palmar hyperhidrosis.
Primary Outcome
Proportion of subjects with at least a 1, 2, or 3 point reduction in Hyperhidrosis Disease Severity Scale (HDSS) score from Baseline
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Dexmecamylamine HCl
Study Locations (3)
California
- Site 02 - San Diego
Missouri
- Site 03 - St Louis
Virginia
- Site 01 - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2017-12-21 |
| Est. Completion | 2019-01-18 |
| Phase | Phase 2 |
What the finished NCT03404570 record still lists
NCT03404570 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Palmar Hyperhidrosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03404570 reports a single indexed study location in California, Missouri, Virginia.
Frequently Asked Questions
What is clinical trial NCT03404570 about?
NCT03404570 is a clinical study titled "Exploratory Study to Assess the Efficacy and Safety of TC-5214 in the Treatment of Subjects With Palmar Hyperhidrosis". This is a pilot exploratory study to evaluate the safety and efficacy of TC-5214 in subjects with palmar hyperhidrosis.
What is the current status of trial NCT03404570?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2017-12-21. Estimated completion is 2019-01-18.
What conditions does trial NCT03404570 study?
This clinical trial studies the following conditions: Palmar Hyperhidrosis.
What interventions are being tested in trial NCT03404570?
The interventions under investigation include: Placebo (OTHER), Dexmecamylamine HCl (DRUG).
Who is sponsoring clinical trial NCT03404570?
This trial is sponsored by Atacama Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03404570 being conducted?
This trial has 3 study locations across California, Missouri, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Palmar Hyperhidrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03404570's enrollment target sits among peer trials
60 1027th of 2000 higher than 868 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI